- Home
- AUTL vs JGH Comparison
AUTL vs JGH Comparison
Compare AUTL & JGH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AUTL | JGH |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 388.6M | 355.2M |
| IPO Year | 2025 | N/A |
Fundamental Metrics
Financial Performance| Metric | AUTL | JGH |
|---|---|---|
| Price | $1.53 | $12.72 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $8.50 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 85.3K |
| Earning Date | 05-14-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.85% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,120,000.00 | N/A |
| Revenue This Year | $80.32 | N/A |
| Revenue Next Year | $53.96 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 496.00 | N/A |
| 52 Week Low | $1.18 | $11.80 |
| 52 Week High | $2.70 | $13.70 |
Technical Indicators
Market Signals| Indicator | AUTL | JGH |
|---|---|---|
| Relative Strength Index (RSI) | 46.27 | 44.28 |
| Support Level | $1.41 | $12.64 |
| Resistance Level | $1.73 | $12.91 |
| Average True Range (ATR) | 0.12 | 0.15 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 29.54 | 10.61 |
Price Performance
Historical ComparisonAbout AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.
About JGH Nuveen Global High Income Fund of Beneficial Interest
Nuveen Global High Income Fund operates as a diversified closed-end management investment company. Its investment objective is to provide a high level of current income. The Fund's securities include U.S. high-yield bonds; non-U.S. high-yield bonds from developed and emerging markets; and other income-producing investments such as preferred and convertible securities.